Early investigational drugs targeting PPAR-α for the treatment of metabolic disease

Zhong Min Liu, Miao Hu, Paul Chan, Brian Tomlinson

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Introduction: The fibrates have been used for many years to treat dyslipidemias and have also recently been shown to have anti-inflammatory effects. They are relatively weak PPAR-α agonists and do have some adverse effects. Novel compounds are in development, which are selective PPAR modulators (SPPARMs) and have more potent PPAR-α agonist activity. These may prove to have advantages in the treatment of dyslipidemia, insulin resistance and non-alcoholic fatty liver disease (NAFLD).Areas covered: This review focuses on PPAR-α agonists or SPPARMs in development describing the preclinical and early clinical studies. The information was obtained by searching the published literature and abstracts from recent meetings. Ongoing clinical trials were identified using the Clinicaltrial.gov database.Expert opinion: There is still a need for new drugs to treat atherogenic dyslipidemia. The highly potent and selective PPAR-α agonist K-877 has shown beneficial effects on atherogenic dyslipidemia and absence of some adverse effects seen with fibrates. The dual PPAR-α/PPAR-δ agonist GFT-505 has shown favorable results in improving atherogenic dyslipidemia and insulin resistance and appears to be a potential candidate for the treatment of NAFLD. Long-term trials are needed to assess the safety and efficacy of these new agents for cardiovascular and liver outcomes.

Original languageEnglish
Pages (from-to)611-621
Number of pages11
JournalExpert Opinion on Investigational Drugs
Volume24
Issue number5
DOIs
Publication statusPublished - May 1 2015

Fingerprint

Investigational Drugs
Peroxisome Proliferator-Activated Receptors
Metabolic Diseases
Drug Delivery Systems
Dyslipidemias
Fibric Acids
Therapeutics
Insulin Resistance
Cardiovascular Agents
Expert Testimony
Anti-Inflammatory Agents
Clinical Trials
Databases
Safety
Liver

Keywords

  • Atherogenic dyslipidemia
  • Fenofibrate
  • GFT-505
  • K-877
  • PPAR-α agonists

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Early investigational drugs targeting PPAR-α for the treatment of metabolic disease. / Liu, Zhong Min; Hu, Miao; Chan, Paul; Tomlinson, Brian.

In: Expert Opinion on Investigational Drugs, Vol. 24, No. 5, 01.05.2015, p. 611-621.

Research output: Contribution to journalArticle

Liu, Zhong Min ; Hu, Miao ; Chan, Paul ; Tomlinson, Brian. / Early investigational drugs targeting PPAR-α for the treatment of metabolic disease. In: Expert Opinion on Investigational Drugs. 2015 ; Vol. 24, No. 5. pp. 611-621.
@article{8d85769d004b4bf6971c8e8704de6400,
title = "Early investigational drugs targeting PPAR-α for the treatment of metabolic disease",
abstract = "Introduction: The fibrates have been used for many years to treat dyslipidemias and have also recently been shown to have anti-inflammatory effects. They are relatively weak PPAR-α agonists and do have some adverse effects. Novel compounds are in development, which are selective PPAR modulators (SPPARMs) and have more potent PPAR-α agonist activity. These may prove to have advantages in the treatment of dyslipidemia, insulin resistance and non-alcoholic fatty liver disease (NAFLD).Areas covered: This review focuses on PPAR-α agonists or SPPARMs in development describing the preclinical and early clinical studies. The information was obtained by searching the published literature and abstracts from recent meetings. Ongoing clinical trials were identified using the Clinicaltrial.gov database.Expert opinion: There is still a need for new drugs to treat atherogenic dyslipidemia. The highly potent and selective PPAR-α agonist K-877 has shown beneficial effects on atherogenic dyslipidemia and absence of some adverse effects seen with fibrates. The dual PPAR-α/PPAR-δ agonist GFT-505 has shown favorable results in improving atherogenic dyslipidemia and insulin resistance and appears to be a potential candidate for the treatment of NAFLD. Long-term trials are needed to assess the safety and efficacy of these new agents for cardiovascular and liver outcomes.",
keywords = "Atherogenic dyslipidemia, Fenofibrate, GFT-505, K-877, PPAR-α agonists",
author = "Liu, {Zhong Min} and Miao Hu and Paul Chan and Brian Tomlinson",
year = "2015",
month = "5",
day = "1",
doi = "10.1517/13543784.2015.1006359",
language = "English",
volume = "24",
pages = "611--621",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Early investigational drugs targeting PPAR-α for the treatment of metabolic disease

AU - Liu, Zhong Min

AU - Hu, Miao

AU - Chan, Paul

AU - Tomlinson, Brian

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Introduction: The fibrates have been used for many years to treat dyslipidemias and have also recently been shown to have anti-inflammatory effects. They are relatively weak PPAR-α agonists and do have some adverse effects. Novel compounds are in development, which are selective PPAR modulators (SPPARMs) and have more potent PPAR-α agonist activity. These may prove to have advantages in the treatment of dyslipidemia, insulin resistance and non-alcoholic fatty liver disease (NAFLD).Areas covered: This review focuses on PPAR-α agonists or SPPARMs in development describing the preclinical and early clinical studies. The information was obtained by searching the published literature and abstracts from recent meetings. Ongoing clinical trials were identified using the Clinicaltrial.gov database.Expert opinion: There is still a need for new drugs to treat atherogenic dyslipidemia. The highly potent and selective PPAR-α agonist K-877 has shown beneficial effects on atherogenic dyslipidemia and absence of some adverse effects seen with fibrates. The dual PPAR-α/PPAR-δ agonist GFT-505 has shown favorable results in improving atherogenic dyslipidemia and insulin resistance and appears to be a potential candidate for the treatment of NAFLD. Long-term trials are needed to assess the safety and efficacy of these new agents for cardiovascular and liver outcomes.

AB - Introduction: The fibrates have been used for many years to treat dyslipidemias and have also recently been shown to have anti-inflammatory effects. They are relatively weak PPAR-α agonists and do have some adverse effects. Novel compounds are in development, which are selective PPAR modulators (SPPARMs) and have more potent PPAR-α agonist activity. These may prove to have advantages in the treatment of dyslipidemia, insulin resistance and non-alcoholic fatty liver disease (NAFLD).Areas covered: This review focuses on PPAR-α agonists or SPPARMs in development describing the preclinical and early clinical studies. The information was obtained by searching the published literature and abstracts from recent meetings. Ongoing clinical trials were identified using the Clinicaltrial.gov database.Expert opinion: There is still a need for new drugs to treat atherogenic dyslipidemia. The highly potent and selective PPAR-α agonist K-877 has shown beneficial effects on atherogenic dyslipidemia and absence of some adverse effects seen with fibrates. The dual PPAR-α/PPAR-δ agonist GFT-505 has shown favorable results in improving atherogenic dyslipidemia and insulin resistance and appears to be a potential candidate for the treatment of NAFLD. Long-term trials are needed to assess the safety and efficacy of these new agents for cardiovascular and liver outcomes.

KW - Atherogenic dyslipidemia

KW - Fenofibrate

KW - GFT-505

KW - K-877

KW - PPAR-α agonists

UR - http://www.scopus.com/inward/record.url?scp=84927602643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927602643&partnerID=8YFLogxK

U2 - 10.1517/13543784.2015.1006359

DO - 10.1517/13543784.2015.1006359

M3 - Article

C2 - 25604802

AN - SCOPUS:84927602643

VL - 24

SP - 611

EP - 621

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 5

ER -